Saint Julien, France


Jubilant Biosys -Saint-Julien-en-Genevois, France


With the acquisition of an established European R&D site in Saint-Julien-en-Genevois, France, Jubilant Biosys enters into Biologics- expanding its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India.


Our R&D site in Saint-Julien-en-Genevois, France will serve as a Center of Excellence for biologics and ADCs, located at the heart of Europe. This expansion strengthens our presence and fosters collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in biologics and ADCs at Saint-Julien-en-Genevois with the capabilities of 1,200 scientists in India we establish a comprehensive service offering for accelerated delivery of early chemistry, discovery biology, DMPK, integrated drug discovery and CDMO for intermediates and APIs. With this strategic move, Jubilant Biosys Limited advances its “CRDMO Partner in Science” strategy and reinforces its commitment to delivering innovative solutions to global pharmaceutical customers.


Jubilant Biosys -Saint-Julien-en-Genevois, France –  Facility Snapshot

  • Size: 42,400 m² state-of-the-art R&D centre
  • Expertise: Discovery and early development in biologics, including ADCs and mAbs
  • Location Advantage: Ideally situated in the EU for local presence and global impact
  • Scientific leadership with over 35 years of ADC/XDC expertise 
  • Proven track record in innovation and early-stage biologics development
  • A European hub offering proximity for seamless collaboration and program oversight


Focus Areas

  • Antibody and ADC discovery
  • Oncology and immuno-oncology
  • In-vitro and in-vivo/ex-vivo biology
  • Analytical and functional characterization